High-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) That Has Not Responded to Previous Low-Dose Intravenous or Subcutaneous Interleukin-2

NCT00080977 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

OTHER

Sponsor class

Conditions

Kidney Cancer

Interventions

BIOLOGICAL: aldesleukin

Sponsor

Blumenthal Cancer Center at Carolinas Medical Center